knowledge -WSS

knowledge

author：focus 2025-09-27 23:03:14 - browse：713

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Biden report: The neurospychology of memory and aging

WSS

Psilocybin's anti

Senators start work on Medicare physician payment reform

2024 GOP presidential candidates spar over abortion in debate

How Long Island became the ‘eugenics capital of the world’

Apellis safety probe of eye disease drug centers on injection needle

Private equity deals in Medicare Advantage declines

hotspot

knowledge

Wikipedia

At least 13 dead in Texas as scorching temps continue

Winners, losers from Medicare’s list of drugs subject to price talks

Medical leaders decry Supreme Court decision on affirmative action

Key House Republican on health care plans exit from Congress

Psychedelics group wrestles with new pharma identity

AstraZeneca bets AAV gene therapy will still deliver the goods

Hollywood unions extend contract negotiations for actors

KalVista pill reduced swelling 'attacks' caused by genetic disease

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What do new weight loss drugs mean for bariatric surgery?

focus

Medicare Advantage proposed rates disappoint insurers

Complete sequence of Y chromosome published for first time

How digital tools helped lower hypertension in marginalized patients

Neuroscience startup Neumora files for IPO

For Medicare Advantage, Democrats want stronger protections around AI

AstraZeneca bets AAV gene therapy will still deliver the goods

hotspot

hotspot

knowledge

knowledge